SCHEMBL7181102

SCHEMBL7181102

COc1cc(OC)c(C(=O)P(C(=O)c2c(COc3ccccc3)cccc2COc2ccccc2)c2ccccc2)c(OC)c1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PARP15 Q460N3 2/20 0.45
PARP10 Q53GL7 2/20 0.45
PTGER1 P34995 1/20 0.44
PTGER4 P35408 1/20 0.44
PTGER3 P43115 1/20 0.44
PTGER2 P43116 1/20 0.44
CD274 Q9NZQ7 9/20 0.43
TDP1 Q9NUW8 1/20 0.42
KMT2A Q03164 2/20 0.41
TP53 P04637 1/20 0.41
CYP3A4 P08684 1/20 0.41
MAPT P10636 1/20 0.41
ATM Q13315 1/20 0.41
HSD17B10 Q99714 1/20 0.41
NPC1 O15118 1/20 0.41
RAB9A P51151 1/20 0.41
FFAR1 O14842 1/20 0.41
FFAR4 Q5NUL3 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.40
MEN1 O00255 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28923145 0.86 CYP3A4 (0.48) KMT2ATP53CYP3A4MAPTATM
SCHEMBL7865371 0.76 CA12 (0.58) KMT2A
SCHEMBL7723212 0.75 TDP1 (0.43) PARP15PARP10PTGER1PTGER4PTGER3
SCHEMBL10276946 0.75 CYP3A4 (0.48) KMT2ATP53CYP3A4MAPTATM
SCHEMBL27509965 0.75 CYP3A4 (0.48) KMT2ATP53CYP3A4MAPTATM
SCHEMBL30929732 0.73 KMT2A (0.48) TDP1KMT2ATP53CYP3A4MAPT
SCHEMBL7601305 0.69 CA12 (0.45)
SCHEMBL5996921 0.68 ABCG2 (0.40) KMT2ATP53CYP3A4MAPTATM
SCHEMBL4779293 0.68 ABCB1 (0.62) PARP10KMT2AMAPTFFAR1L3MBTL1
SCHEMBL30442322 0.66 RXRA (0.55) KMT2ATP53ATMNPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6579663-B2 Chemical intermediates such as lithium 2,6-dimethylbenzoyl phenylphosphine for preparation of acylphosphines, acylphosphine oxides or acylphosphine sulfides CIBA SPECIALTY CHEMICALS CORPORATION 2003-06-17 US disclosed
US-20020107413-A1 Organometallic monoacylarylphosphines WOLF JEAN-PIERRE (CH) 2002-08-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020107413-A1 Organometallic monoacylarylphosphines CBR1, NAF1, DHCR24 PARP15 3054/4885PARP10 1658/4885PTGER1 3015/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.